LY2603618, Chk1 inhibitor

Product Details

Formal Name: N-[5-bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy]phenyl]-N’-(5-methyl-2-pyrazinyl)urea

Alternate Names: Rabusertib

Molecular Formula: C₁₈H₂₂BrN₅O₃

Formula Weight: 436.30

CAS Number: 911222-45-2

Purity: >98%

Formulation: powder

Solubility: Soluble in DMSO (up to 10 mg/ml)

Storage: -20°C

Stability: ≥ 1 year.

Applications

Chk1 inhibitor

Functions

LY2603618 is a potent (IC50 = 7nM) and selective (>1000x over Chk2) Checkpoint kinase 1 (Chk1) inhibitor. Chk1 is an important regulator of the DNA damage response – combination treatment of LY2603618 with other chemotherapeutic agents significantly increased tumor growth inhibition when compared to chemotherapeutic alone. LY2603618 caused a dramatic suppression of cell growth in MCF-7 and MDA-MB-231 human breast cancer cells via Chk1 inhibition induced upregulation of replication stress caused by oncogenes.

Application Procedures

First dissolved in DMSO (up to 10 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20°C for up to 3 months.

Research use only.

Documents

• Datasheet (PDF)